Home > Products > Antibodies > Biosimilars

Research Grade Faricimab (HT073016)

Price(USD): $
Spec:
  • 100ug
  • 1mg
Number:
Contact us
  • Overview
  • Images
  • References
  • Datasheet
Overview
Catalog No.HT073016
Species reactivityHuman
ApplicationsResearch Grade Biosimilar
Host speciesHumanized
IsotypeIgG1-kappa-lambda
Expression systemMammalian Cells
ClonalityMonoclonal
TargetVascular endothelial growth factor A, VPF, VEGFA, VEGF, Vascular permeability factor, VEGF-A, ANG-2, ANGPT2, Angiopoietin-2
Concentration11.9mg/ml
Endotoxin levelPlease contact the lab for this information.
Purity>95% purity as determined by SDS-PAGE.
PurificationProtein A/G, purified from cell culture supernatant.
AccessionP15692 & O15123
FormLiquid
Storage buffer20mM His,140mM NaCl,pH6.0
Stability and StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -401°C.
Alternate NamesBispecific,RG7716,RO6867461,CAS:1607793-29-2
BackgroundFaricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO).
NoteFor research use only. Not for use in clinical or therapeutic applications.
Images
  • SDS-PAGE

    SDS-PAGE for Research Grade Faricimab

  • Bioactivity

    Detects Human ANGPT2 in indirect ELISAs.

  • Bioactivity

    Detects VEGFA in indirect ELISAs.

Recommendation